Atopic dermatitis: dupilumab shows good efficacy and safety in 3-year LIBERTY AD OLE

  • Beck LA & al.
  • Am J Clin Dermatol
  • 17 Jun 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with moderate to severe atopic dermatitis, dupilumab is associated with sustained clinical improvement and a stable safety profile, according to a 3-year open-label extension study (LIBERTY AD OLE).

Why this matters

  • These results suggest that dupilumab is an appropriate continuous treatment choice in this patient group.

Key results

  • Mean self-reported drug adherence was 98.2%.
  • At week 148, mean improvement in the Eczema Area and Severity Index was −95.4% compared with baseline.
  • At week 148, mean improvement in the Pruritus Numerical Rating Scale was −65.4% compared with baseline.
  • The rate of adverse events was 270.1 per 100 patient-years.
  • The rate of serious adverse events was 6.92 per 100 patient-years.
  • The most common adverse events (≥5% of patients) were nasopharyngitis, atopic dermatitis, upper respiratory tract infection, conjunctivitis, headache, oral herpes, and injection-site reaction.

Study design

  • Of 2677 patients with atopic dermatitis originally enrolled and treated, 347 reached week 148 and were analyzed for efficacy and safety.
  • Funding: Sanofi, Regeneron Pharmaceuticals, Inc.

Limitations

  • Open-label study.
  • Nonapproved dosage was used.